Rocket Pharmaceuticals Announces Preliminary Data from Phase 1/2 Trial of RP-L201 for Leukocyte Adhesion Deficiency-I
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Rocket Pharmaceuticals (RCKT) PT Raised to $33 at Chardan Capital Markets
December 9, 2019 8:02 AM ESTChardan Capital Markets analyst Geulah Liveshits raised the price target on Rocket Pharmaceuticals (NASDAQ: RCKT) to $33.00 (from $30.00) while maintaining a Buy rating.
The analyst commented, "On 8 November, Rocket Pharmaceuticals presented preliminary data on ex vivo lentiviral gene therapy RP-L102 for Fanconi anemia (FA), manufactured with commercial-grade "Process B", demonstrating (1) 2-3x higher product vector copy numbers (VCNs) vs. Process A product, and (2) signals of engraftment in patients at 6 months. The data, presented in a poster at the American Society of Hematology (ASH) 2019 Annual... More
